B7-1/CD80 Antibody (IDEC-114 (Galiximab)) - Azide and BSA Free

Novus Biologicals, part of Bio-Techne | Catalog # NBP2-81099

Recombinant Monoclonal Antibody
Novus Biologicals, part of Bio-Techne

Key Product Details

Species Reactivity

Human

Applications

Block/Neutralize, ELISA, Flow Cytometry, Functional, Immunohistochemistry, Immunoprecipitation, Western Blot

Label

Unconjugated

Antibody Source

Recombinant Monoclonal Human IgG1 Lambda Clone # IDEC-114 (Galiximab)

Format

Azide and BSA Free

Concentration

1 mg/ml

View all B7-1/CD80 Antibodies »

Product Specifications

Immunogen

Galiximab was prepared by immunizing cynomolgus monkeys with recombinant B7-1/CD80 antigen. The variable regions of the light and heavy chains were then cloned by being incorporated into a cassette vector (N5LG1) containing human constant region genes and subsequently transfected into the Dg44 CHO cell line (Hariharan K, 2013)

Specificity

Galiximab is a primatized mAb which consists of human constant and primate (cynomolgus macaque) variable regions and binds specifically to B7-1/CD80. B7-1/CD80 is a surface glycoprotein and a member of the B7 family of costimulatory molecules. B7-1/CD80 antigen regulates T cell activation (through interacting with CD28 or CD152) and is expressed transiently in antigen-presenting cells, T cells and normal B cells, and expressed consitutively on various subtypes of B-cell lymphomas.

Clonality

Monoclonal

Host

Human

Isotype

IgG1 Lambda

Scientific Data Images for B7-1/CD80 Antibody (IDEC-114 (Galiximab)) - Azide and BSA Free

B7-1/CD80 Antibody (IDEC-114 (Galiximab)) [NBP2-81099] - Immunofluorescence staining of fixed Daudi cells with anti-CD80 antibody IDEC-114 (Galiximab) (Ab00736) Immunofluorescence analysis of paraformaldehyde fixed Daudi cells on coverslips, permeabilized with 0.15% Triton and stained with the chimeric rabbit IgG version of IDEC-114 (Galiximab) at 10 ug/mL for 1h followed by Alexa Fluor 488 secondary antibody (1 ug/ml), showing membrane staining. The nuclear stain is DAPI (blue). Panels show from left-right, top-bottom Galiximab, DAPI, merged channels and an isotype control. The isotype control was stained with an anti-Fluorescein antibody followed by Alexa Fluor 488 secondary antibody.

Applications for B7-1/CD80 Antibody (IDEC-114 (Galiximab)) - Azide and BSA Free

Application
Recommended Usage

Block/Neutralize

Optimal dilutions of this antibody should be experimentally determined.

ELISA

Optimal dilutions of this antibody should be experimentally determined.

Flow Cytometry

Optimal dilutions of this antibody should be experimentally determined.

Functional

Optimal dilutions of this antibody should be experimentally determined.

Immunohistochemistry

Optimal dilutions of this antibody should be experimentally determined.

Immunoprecipitation

Optimal dilutions of this antibody should be experimentally determined.

Western Blot

Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Galiximab acts to decrease in cell proliferation, inhibition of the constitutively active NF-kappaB pathway, increase in apoptosis and ADCC against various B-cell lymphoma cell lines. Galiximb affects CD28 and CD152 interactions with CD80. This antibody can also be used for FC, WB, ELISA, IP and IHC.

Formulation, Preparation, and Storage

Purification

Protein A purified

Formulation

PBS

Format

Azide and BSA Free

Preservative

0.02% Proclin 300

Concentration

1 mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C for up to 3 months. For longer storage, aliquot and store at -20C.

Background: B7-1/CD80

The B-lymphocyte activation antigen B7-1 (CD80) provides regulatory signals for T lymphocytes as a consequence of binding to the CD28 and CTLA4 ligands of T cells. After engagement of T-cell receptor with antigen in association with major histocompatibility complex class II, a second signal mediated through the binding of B7 to CD28 greatly upregulates the production of multiple lymphokines (1). The relatively small CTLA-4/B7-1 binding interface exhibits an unusually high degree of shape complementarity. CTLA-4 forms homodimers through a newly defined interface of highly conserved residues. This zipper-like oligomerization provides the structural basis for forming unusually stable signalling complexes at the T-cell surface, underscoring the importance of potent inhibitory signalling in human immune responses (2).

Alternate Names

B71, CD80

Gene Symbol

CD80

Additional B7-1/CD80 Products

Product Documents for B7-1/CD80 Antibody (IDEC-114 (Galiximab)) - Azide and BSA Free

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for B7-1/CD80 Antibody (IDEC-114 (Galiximab)) - Azide and BSA Free

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.